OGN

Business Context and Reporting Period

Company: Organon & Co.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Organon is a global healthcare company focused on women's health and general medicines, including biosimilars. The company operates six manufacturing facilities globally and sells products in over 140 countries.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Worldwide sales decreased 2% in Q2 and 3% YTD compared to 2025. Excluding foreign exchange, the decline was 5% in Q2 and 7% YTD.
• Product Performance:
  • Declines: Nexplanon sales fell 12% YTD due to delayed reinsertions and funding uncertainty. Singulair sales dropped 37% YTD due to unfavorable guidelines and price reductions. Ontruzant sales fell 77% YTD due to lower tender volumes in Brazil. Jada sales were zero following its divestiture in January 2026.
  • Increases: Hadlima sales grew 51% YTD driven by US demand. Emgality sales increased 45% YTD. Zetia/Vytorin sales rose 8% YTD driven by China demand.
• Restructuring Costs: Restructuring expenses decreased significantly to $31 million YTD 2026 from $88 million YTD 2025, reflecting a 3% headcount reduction in 2026 versus 6% in 2025.
• One-Time Gains: The company recognized an $81 million net gain on the sale of the Jada System in Q1 2026, which positively impacted YTD net income and cash flow.
• Interest Expense: Decreased 14% YTD to $219 million due to debt repurchases in 2025 and mandatory prepayments from Jada proceeds.

Outlook, Risks, and Unusual Items

• Acquisition by Sun Pharma: On April 26, 2026, Organon entered a definitive agreement to be acquired by Sun Pharmaceutical Industries Limited for $14.00 per share in cash. Stockholder approval was received on July 23, 2026, with closing expected in early 2027.
• Divestiture: The Jada System was sold to Laborie Medical Technologies in January 2026 for up to $465 million (including contingent consideration).
• Legal Proceedings:
  • Nexplanon Sales Investigation: The company voluntarily disclosed an internal investigation to the SEC regarding Nexplanon sales to certain US wholesalers. The SEC has opened an investigation.
  • Product Liability: Settlement agreements were reached for the majority of Fosamax (femur fracture) and Nexplanon/Implanon lawsuits in New Jersey, California, and Ohio, with payments described as confidential and non-material.
  • Patent Litigation: Generic applications (Paragraph IV certifications) were received for Vtama from three manufacturers (Encube, Mylan, Natco) in July 2026.
• Internal Controls: Management concluded that material weaknesses in internal control over financial reporting (related to tone at the top and information communication) identified in 2025 have been remediated as of June 30, 2026.
• Dividends: A quarterly dividend of $0.02 per share was declared on July 31, 2026.

Investor Verification Checklist

• Transaction Closing: Verify the status of regulatory approvals and the expected closing date for the Sun Pharma acquisition.
• Nexplanon Demand: Monitor the impact of the five-year label approval and federal funding uncertainty on reinsertion volumes and future sales.
• SEC Investigation: Track the outcome of the SEC investigation into Nexplanon wholesaler sales practices and potential financial or reputational impact.
• Patent Expirations: Assess the timeline and potential impact of generic entry for Vtama and the 2027 patent expiration for Nexplanon.
• Debt Obligations: Review the schedule of mandatory debt prepayments required following the Jada divestiture and the company's liquidity position.